Rare PUF60 Gene Changes Cause a Spectrum of Developmental and Multisystem Disorders
A GeneReviews entry details PUF60-related disorders: features, diagnosis, multidisciplinary care, and inheritance in the 84 people identified to date.
Resumen
PUF60-related disorders are rare genetic conditions caused by a pathogenic variant in the PUF60 gene or a deletion of the 8q24.3 region that includes it. Most affected people have mild-to-moderate developmental delay, often with short stature, low muscle tone, and skeletal differences. A small number have a more severe presentation, historically called Verheij syndrome, with seizures, iris coloboma, heart defects, and marked developmental delay. Eighty-four individuals have been identified so far. Diagnosis rests on molecular genetic testing. Care is supportive and involves many specialists, with regular follow-up to track existing and new problems. The condition is autosomal dominant and usually arises de novo, though inheritance from a parent is occasionally seen. Each child of an affected person has a 50% chance of inheriting it, and prenatal or preimplantation testing is possible once the familial alteration is known.
Resumen detallado
Why this matters: PUF60-related disorders are ultra-rare, and their variable presentation can make recognition difficult. Clear clinical guidance helps clinicians identify affected patients, coordinate care, and counsel families. This is a GeneReviews chapter, a curated expert clinical resource, and was written by authors affiliated with an aging-biology institute.
What was covered: The chapter summarizes the clinical spectrum, diagnostic criteria, management, and genetic counseling for conditions caused by changes in PUF60. These include heterozygous pathogenic variants and contiguous gene deletions of 8q24.3 that include PUF60. The abstract reports 84 identified individuals.
Key points: The phenotype is a continuum. Most people have mild-to-moderate developmental delay with variable features, most often short stature, muscular hypotonia, and skeletal involvement. Rarely, the severe form (Verheij syndrome) occurs, with seizures, iris coloboma, congenital cardiac defects, short stature, and skeletal anomalies. Diagnosis is confirmed by molecular testing in a person with suggestive findings.
Implications: Management is multidisciplinary, drawing on genetics, neurology, audiology, ophthalmology, developmental therapies, feeding specialists, cardiology, pulmonology, gastroenterology, immunology, endocrinology, nephrology, urology, and orthopedics. Scheduled follow-up monitors known manifestations and new ones. The disorder is autosomal dominant, usually de novo, with a 50% transmission risk to offspring of affected individuals and options for prenatal and preimplantation testing.
Caveats: Only the abstract was available, so details on specific variants, prevalence, and surveillance schedules are not covered here. With only 84 known cases, the described spectrum may shift as more people are identified. The chapter describes no disease-specific cure or targeted therapy.
Hallazgos clave
- PUF60-related disorders form a continuum, most often mild-to-moderate developmental delay with variable multisystem features.
- Common features include short stature, muscular hypotonia, and skeletal involvement.
- Severe cases (Verheij syndrome) involve seizures, iris coloboma, congenital heart defects, and marked neurodevelopmental delay.
- Diagnosis requires a heterozygous PUF60 pathogenic variant or an 8q24.3 deletion including PUF60.
- Autosomal dominant, usually de novo; 50% recurrence risk for children of affected individuals.
Metodología
This is an expert-authored GeneReviews clinical synopsis, not a primary study. It synthesizes published case reports and cohort data on 84 identified individuals with PUF60-related disorders. Only the abstract was available for this summary.
Limitaciones del estudio
Based on the abstract only, so detailed recommendations and variant-level data are not captured. The small number of reported cases limits understanding of the full phenotype and natural history. Management is supportive, with no targeted treatment described.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte:
